Welcome to our dedicated page for Adverum Biotech news (Ticker: ADVM), a resource for investors and traders seeking the latest updates and insights on Adverum Biotech stock.
Adverum Biotechnologies, Inc. (NASDAQ: ADVM) is a clinical-stage gene therapy pioneer developing innovative treatments for ocular and rare diseases through its proprietary intravitreal platform. This resource provides investors and medical professionals with essential updates on the company's clinical trials, regulatory milestones, and strategic initiatives.
Access real-time information about ADVM's AAV-based therapies designed to reduce treatment burdens in conditions like wet AMD. The page aggregates official press releases, partnership announcements, and trial result disclosures - critical data for evaluating the company's progress in advancing durable single-dose therapies.
Key content includes updates on lead candidates like the wet AMD gene therapy program, manufacturing developments, and peer-reviewed research publications. Track progress across therapeutic areas including ophthalmology and rare genetic disorders through verified company communications.
Bookmark this page for streamlined access to ADVM's latest scientific advancements and corporate updates. Check regularly for new developments in their mission to transform chronic disease management through groundbreaking gene therapy approaches.
Adverum Biotechnologies (ADVM), a clinical-stage company focused on gene therapy for ocular diseases, has announced its participation in three upcoming investor conferences:
- H.C. Wainwright 26th Annual Global Investment Conference on September 10th at 3:30 p.m. ET
- Chardan's 8th Annual Genetic Medicines Conference on October 1st at 8:00 a.m. ET
- UBS Virtual Ophthalmology Day on October 2nd at 10:30 a.m. ET
On-demand webcasts of these presentations will be available in the Investors section of Adverum's website under Events and Presentations. Replays will be accessible for at least 30 days following each event.
Adverum Biotechnologies (ADVM) reported its Q2 2024 financial results and provided updates on its Ixo-vec program for wet AMD treatment. Key highlights include:
1. Selection of 6E10 dose for Phase 3 pivotal trials based on LUNA 26-week interim analysis.
2. $173.8 million in cash and equivalents, expected to fund operations into late 2025.
3. LUNA trial showed 76% of 6E10 patients were injection-free at 26 weeks.
4. Ixo-vec received RMAT designation from FDA.
5. Q2 2024 net loss of $18.5 million, or $0.89 per share.
6. Anticipated milestones include LUNA 9-month analysis and Phase 3 trial design update in Q4 2024.
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company focused on gene therapy for ocular diseases, has announced its participation in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference. The company's president and CEO, Laurent Fischer, M.D., will take part in a fireside chat on August 15, 2024, at 2:00 p.m. ET.
Interested parties can access the webcast of the fireside chat through the Events and Presentations section of Adverum's website, located in the Investors area. The replay of the webcast will remain available on the website for a minimum of 30 days following the presentation, allowing those unable to attend the live event to catch up on the discussion.
Adverum Biotechnologies (Nasdaq: ADVM) has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for Ixo-vec, its gene therapy candidate for treating wet AMD. This designation, along with the previously granted PRIME designation, recognizes Ixo-vec's potential to address unmet medical needs in nAMD treatment. The RMAT program, established under the 21st Century Cures Act, aims to expedite development and review of promising therapies for serious conditions.
RMAT designation offers benefits such as intensive FDA guidance on efficient drug development and potential priority review of the biologics license application (BLA). Adverum plans to share updates from regulatory discussions in Q4 2024.
Adverum Biotechnologies (Nasdaq: ADVM) presented positive 26-week interim results from the LUNA Phase 2 trial of Ixo-vec for wet AMD at the 2024 ASRS Annual Meeting. Key findings include:
1. The 6E10 dose with local prophylaxis was selected for Phase 3 trials.
2. 76% of 6E10 patients were injection-free at 26 weeks.
3. 100% of 6E10 difluprednate-alone patients had no or minimal inflammation.
4. 88% of patients preferred Ixo-vec over prior anti-VEGF injections.
5. Efficacy and safety with 6E10 at 26 weeks were similar to or better than OPTIC at 2E11.
The company plans to present 9-month data and pivotal trial design updates in Q4 2024, with Phase 3 trials expected to begin in H1 2025.
Adverum Biotechnologies (Nasdaq: ADVM) has announced plans to host a webcast on July 17, 2024, to review the 26-week interim data from its ongoing LUNA Phase 2 trial. The trial evaluates ixoberogene soroparvovec (Ixo-vec) for treating wet age-related macular degeneration (wet AMD). This data will be presented at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting. Dr. Charles C. Wykoff, a key investigator in the LUNA study, will lead the presentation. The webcast will start at 8:00 a.m. ET, with the ASRS presentation scheduled for 8:45 a.m. CEST. Both the live webcast and a subsequent replay will be accessible on Adverum’s website.
Adverum Biotechnologies (Nasdaq: ADVM), a clinical-stage company focused on gene therapy for ocular diseases, announced its participation in TD Cowen’s Genetic Medicines & RNA Summit.
Laurent Fischer, M.D., the company's president and CEO, will engage in a fireside chat at the summit on June 21, 2024, at 10:00 a.m. ET.
The event will be webcasted live and accessible via Adverum's website under the Investors section, with a replay available for at least 30 days post-event.
Adverum Biotechnologies announced the appointments of Dr. Rabia Gurses Ozden as Chief Medical Officer and Dr. Szilárd Kiss as a Board Member, effective June 11, 2024. Dr. Ozden, with over 20 years in ophthalmology drug development, transitions from the board to the executive team, bringing her expertise in clinical development and gene therapies. Dr. Kiss, an experienced retina specialist and gene therapy expert, will fill Ozden's vacated board seat. Their contributions are expected to advance Adverum's Ixo-vec gene therapy for wet AMD, particularly through the LUNA trial and pivotal studies.
Adverum Biotechnologies, Inc. (Nasdaq: ADVM) reported Q1 2024 financial results and pipeline highlights, showcasing strong cash position, positive preliminary data from the LUNA trial, and upcoming milestones. The company presented a 26-week interim analysis at ASRS on Ixo-vec for wet AMD, with promising reduction in injections and good tolerability. Financially, the company's cash, cash equivalents, and short-term investments increased to $193.3 million, supporting operations into late 2025.
Adverum Biotechnologies, Inc. (Nasdaq: ADVM) will participate in upcoming investor conferences in May 2024 to showcase its gene therapy for ocular diseases. The company will present at the 2024 RBC Global Healthcare Conference, BofA Securities 2024 Health Care Conference, and H.C. Wainwright 2nd Annual BioConnect Investor Conference. Investors can access the webcast on Adverum's website.
FAQ
What is the current stock price of Adverum Biotech (ADVM)?
What is the market cap of Adverum Biotech (ADVM)?
